分享产品介绍 评论(0)
物种
Rat分子别名
IL-17A, Interleukin-17A, CTLA-8, IL-17, IL-17F, Interleukin-17F, Cytokine ML-1, IL17A&IL17FAccession
Q61453 (IL-17A), Q5BJ95 (IL-17F)表达序列
Ala18-Ser150(IL-17A)
Arg29-Ala161 (IL-17F)表达宿主
HEK293分子量
12-25 kDa (Reducing)
纯度
>95% by SDS-PAGE and HPLC.内毒素含量
<0.1EU/μg活性
EC50 = 33.5-46.61 ng/mL标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Annu Rev Immunol. 2009:27:485-517.
Interleukin-17A (IL-17A), also called cytotoxic T-lymphocyte-associated antigen 8 (CTLA8), and IL-17F are proinflammatory cytokines primarily secreted by activated T cells. Both cytokines can modulate the activities of NF-kappaB and mitogen-activated protein kinases, playing key roles in inflammatory signaling pathways. They are capable of stimulating the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), while also enhancing the production of nitric oxide (NO). Both IL-17A and IL-17F exist in both glycosylated and nonglycosylated forms, which may affect their biological activities. These two cytokines often work in concert to amplify inflammatory responses in the body. Elevated levels of IL-17A and IL-17F are associated with various chronic inflammatory diseases. Such diseases include rheumatoid arthritis, psoriasis, and multiple sclerosis, highlighting their significance in pathological processes.
电泳
2μg (R: reducing condition, N: non-reducing condition).
体积排阻色谱(SEC-HPLC)
>95% as determined by SEC-HPLC.
ELISA
Immobilized IL-17A&IL-17F Protein, Rat (Cat. No. UA040489) at 2.0μg/mL (100μL/well) can bind Human IL-17 RA / CD217 Protein, Fc Tag with EC50 of 33.5-46.61 ng/mL.
评论(0)